The Indian Ministry of Health has directed states to stop the sale and distribution of nicotine pouches, officially classifying them as unapproved drugs. This move closes a regulatory loophole that allowed brands like Zyn to enter the market. The decision aims to curb youth addiction and reinforces that no new nicotine formulations will be permitted for sale in the country.
The Indian government has taken a decisive regulatory stance against nicotine pouches, issuing a directive in September 2026 that classifies these products as unapproved drugs. This action effectively halts the sale, import, and distribution of such products across the country, aiming to address public health concerns related to youth usage and potential addiction.
The core of the regulatory challenge lies in how these products were previously positioned. While they contain nicotine, they did not fall under the existing framework of the Cigarettes and Other Tobacco Products Act (COTPA), which governs traditional tobacco items. By categorizing them as unapproved drugs under the Drugs and Cosmetics Act, health authorities have established that these products lack the necessary safety authorizations required to be sold as pharmaceutical or consumer goods in India.
Following this directive, the Drugs Technical Advisory Board (DTAB) has also recommended against the approval of any new nicotine formulations. This recommendation creates a high barrier to entry for international brands, including major players like Philip Morris International, whose Zyn brand had been identified in the Indian market. For investors and businesses, this represents a significant shift in market access. The classification as unapproved medicines implies that any commercial activity involving these pouches can be treated as a violation of drug control regulations, exposing distributors and retailers to legal scrutiny and product seizures.
Health agencies, including the Indian Council of Medical Research, have been vocal about the risks associated with these products, particularly regarding their appeal to younger demographics and their potential impact on brain and cardiovascular health. The government’s move is intended to prevent the establishment of a market segment that health officials view as a public health risk rather than a safe alternative to traditional tobacco.
For stakeholders, the primary monitorable is the pace of enforcement by state authorities. As officials move to implement the ban, the focus will remain on the removal of these products from online platforms and retail outlets. The ruling underscores the government's prioritize of public health safety standards over the expansion of unregulated niche product categories. Future updates may include further clarity on the penalties for non-compliance and the extent of product recalls in the coming months.